AlphaThera News & Updates

Track our progress, grant history, and new developments.
8 Results
Grant Award
02/22/2023
$1.7M NIH SBIR Phase II Grant Awarded to AlphaThera for Development of ADCs to target Pancreatic Cancer

AlphaThera was awarded an SBIR Phase II grant by the NIH/NCI to further development of ADCs generated by proximity-based sortase-mediated ligation.

Read more
Grant Award
10/12/2021
Supplemental $50,000 NIH TABA funding awarded to AlphaThera to support scaled commercialization of Site-specific Antibody Labeling Technology

The TABA supplemental funding will go directly towards supporting scaled commercialization activities of AlphaThera’s site-specific antibody labeling technology.

Read more
Grant Award
08/25/2020
AlphaThera Awarded $667,000 SBIR Phase II Grant Extension for COVID-19 Detection Products

AlphaThera was awarded a grant to research & commercialize conjugation technologies that will assist in scale-up of COVID-19 serological assays to meet demand for daily testing.

Read more
Grant Award
03/04/2020
NIH Grant Awarded to AlphaThera for Targeted Degradation of Cytosolic Proteins

AlphaThera was awarded an NIH Grant for research into Trim21-mediated degradation of antibody-targeted cytosolic proteins.

Read more
Grant Award
09/01/2018
NIH Grant Awarded to AlphaThera for Antibody-MNase Conjugation

AlphaThera was awarded an NHI/NHLBI Grant to fund research for Photoreactive Antibody-Binding Domain-Microccocal Nuclease Conjugates ((pAbBD)-MNase).

Read more
Grant Award
08/01/2018
NIH Phase II Grant to AlphaThera for Antibody Site-Specific Immobilization & Labeling

AlphaThera was awarded an NIH Phase II Grant for continued research into site-specific labeling and immobilization of antibodies for immunoassays.

Read more
Grant Award
08/01/2017
NIH Grant Awarded to AlphaThera for Site-Specific ADCs by PBSL

AlphaThera awarded a grant by the NIH/NCI to fund research for Site-specific Antibody-Drug Conjugates by proximity-based sortase ligation.

Read more
Grant Award
04/01/2017
NIH Grant Awarded to AlphaThera for Site-Specific Antibody Immobilization for Immunoassays Grant Award

AlphaThera was awarded an NIH/NIBIB Grant to fund research for designing Tools for Site-Specific Antibody Immobilization for Immunoassays.

Read more
6 Results
Media
09/10/2025
Relocation Marks Next Step in AlphaThera’s Expansion

AlphaThera today announced its relocation to a significantly larger laboratory and office facility at 3675 Market Street in the heart of Philadelphia’s University City, marking an important milestone in the company’s growth. The move will provide the company with twice the space of their existing location, combining both laboratory and office space to allow for […]

Read more
Media
12/08/2023
AlphaThera relocates to accommodate the company’s rapid expansion

AlphaThera have announced their relocation to a new larger laboratory and office space within the Pennovation Works Lab Building at the University of Pennsylvania.

Read more
Media
04/01/2021
AlphaThera Interview: Penn Center for Innovation interviews co-founder Dr. Andrew Tsourkas

AlphaThera’s co-founder, Dr. Andrew Tsourkas, was featured in a speaker event “Moving Ideas to Market: A Discussion with Entrepreneurs & Researchers” hosted by Penn Center for Innovation

Read more
Media
02/01/2021
AlphaThera in the News: oYo-Link™ Oligo Product Spotlight with Pennovation Center

Pennovation Works featured a product spotlight for AlphaThera’s oYo-Link™ Oligo Custom conjugation product.

Read more
Media
12/08/2020
AlphaThera Interview: Colliers LabNotes interviews AlphaThera co-founder Dr. Andrew Tsourkas

Joe Fetterman of Colliers LabNotes interviews AlphaThera co-founder Dr. Andrew Tsourkas about his backstory & path toward founding AlphaThera.

Read more
Media
09/24/2020
AlphaThera in the News: The Daily Pennsylvanian

UPenn’s prominent independent newspaper, the Daily Pennsylvanian, featured an article about AlphaThera’s recent COVID-19 grant award.

Read more
4 Results
Partnerships, Product Launch
06/04/2024
Columbia Biosciences and AlphaThera partner to develop range of Site-Specific Fluorescent Protein Labeling Reagents

The partnership will provide the life science market with an innovative conjugation chemistry for antibody labeling.

Read more
Partnerships
12/09/2021
Expansion of AlphaThera’s Distributor Network supports worldwide delivery of oYo-Link Antibody Labeling Technology

AlphaThera has announced the further expansion of its distributor network as interest in their oYo-Link Site Specific Antibody Labeling Technology continues to grow on an international scale.

Read more
Partnerships
10/15/2021
oYo-Link® Products Now Available to Purchase through Quartzy

AlphaThera has teamed up with Quartzy to make their oYo-Link Antibody labeling products conveniently available to researchers for purchase.

Read more
Partnerships
09/09/2021
Funakoshi Co., Ltd. Announced as AlphaThera’s Distribution Partner in Japan

AlphaThera has announced a distribution agreement with Funakoshi Co., Ltd. to deliver oYo-Link® Antibody labeling products to researchers in Japan.

Read more
5 Results
Partnerships, Product Launch
06/04/2024
Columbia Biosciences and AlphaThera partner to develop range of Site-Specific Fluorescent Protein Labeling Reagents

The partnership will provide the life science market with an innovative conjugation chemistry for antibody labeling.

Read more
Product Launch
04/13/2023
AlphaThera announces the launch of oYo-Capture™ Magnetic Beads

For the efficient removal of free oYo-Link® post conjugation AlphaThera has announced the launch of oYo-Capture™ Magnetic Beads, providing researchers with an efficient method of removing free oYo-Link® reagents post antibody conjugation to ensure low background in high sensitivity assays. AlphaThera is well known within the life science research community for their oYo-Link® antibody labeling […]

Read more
Product Launch
01/30/2023
AlphaThera launches oYo-Link® Horseradish Peroxidase (HRP)

AlphaThera has announced the launch of oYo-Link® Horseradish Peroxidase (HRP), the latest addition to their range of site-specific antibody labeling reagents. The oYo-Link antibody-HRP labeling technology will enable the rapid production of highly uniform primary antibody conjugates in under two hours, and with only 30 seconds hands-on time.

Read more
Product Launch
06/20/2022
AlphaThera Expand Their Range of oYo-Link Antibody-Drug Conjugate Reagents

AlphaThera have announced the addition of DM4 to their range of oYo-Link® Antibody-Drug Conjugation Reagents which also includes VcMMAE, VcMMAF and DM1.

Read more
Product Launch
04/20/2020
AlphaThera Launches oYo-Link® Epitope Tag for Enhanced Multiplexing Capability

AlphaThera has announced the launch of oYo-Link® Epitope Tag, the latest addition to their range of site-specific antibody labeling reagents.

Read more
4 Results
Publication
02/07/2022
AlphaThera Highlighted in Nature Methods Article: “How single-cell multi-omics builds relationships”

Dr. Andrew Tsourkas and Dr. Feifan Yu interview about oYo-Link Oligo technology and its potential within the field of multi-omic single-cell analysis.

Read more
Publication
05/24/2021
AlphaThera & Penn Researchers’ Publication: Efficient native IgG labeling for ADC Production

AlphaThera members & Penn researchers worked to publish a high-impact publication in Bioconjugate Chemistry titled “Efficient Labeling of Native Human IgG by Proximity-Based Sortase-Mediated Isopeptide Ligation”.

Read more
Publication
01/13/2021
Publication Feature: “Targeting cartilage EGFR pathway for osteoarthritis treatment” Science Translational Medicine

Read how a research team used AlphaThera’s site-specific bioconjugation technique to seed nanoparticles with a TGFa payload.

Read more
Publication
10/07/2020
AlphaThera in the News: Atlas of Science

A layman’s summary of AlphaThera’s LASIC site-specific Antibody labeling technology was published by the Atlas of Science.

Read more